DE vs PFE: Which Is the Better Buy?
Side-by-side comparison of Deere & Company and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-23.
Deere & Company · Industrials
$703.12
-12.2% upside to fair value
Med Conviction
Grade C
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+12.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DE |
PFE |
| Current Price |
$703.12 |
$27.64 |
| Fair Value Estimate |
$616.99 |
$30.94 |
| Upside to Fair Value |
-12.2%
|
+12.0%
|
| Market Cap |
$189.8B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
22.1x
|
17.4x
|
| Price / Sales |
4.0x
|
2.5x
|
| Price / FCF |
49.1x
|
14.3x
|
| Revenue Growth YoY |
+7.0%
|
+2.6%
|
| Gross Margin |
35.7%
|
71.3%
|
| Operating Margin |
19.0%
|
25.1%
|
| Return on Equity |
18.1%
|
4.9%
|
| Dividend Yield |
0.92% |
6.22% |
| FCF Yield |
2.04%
|
6.97%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Deere & Company is a 1837-founded global manufacturer of agricultural, turf, and construction equipment organized across Production and Precision Agriculture, Small Agriculture and Turf, Construction and Forestry, and Financial Services, employing roughly 73,100 people under CEO John C. May. Business quality is high on franchise strength but currently strained by the large-agriculture cycle: TTM …
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
DE |
PFE |
| Zone Low |
$462.74 |
$23.21 |
| Zone High |
$524.44 |
$26.30 |
| In Buy Zone? |
No
|
No
|